drug
gepotidacin mesylate
Marketedupdated 5mo agoby GlaxoSmithKline LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(2)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 11, 2028
~2.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Dec 13, 2042compositionUS 12528809
- Aug 20, 2035method-of-use (U-4361)US 10702521
- Aug 20, 2035method-of-use (U-4361)US 11229646
- Feb 12, 2029compositionUS 83895242.4y
FDA exclusivities (3)
- Mar 25, 2035GAINGAIN Antibiotic (5y)
- Mar 25, 2030NCENew Chemical Entity (5y)3.5y
- Dec 11, 2028I-978Indication (3y)2.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that